Mohammad Reza Hajian 1
, Hamid Reza Jahantigh 2
, Shahrzad Alimohammadi 3,4
, Zahra Mojtahedi 5
, Neda Kianpour 6
, Majid Foroutan 7* 1
Nickan Research Institute, Isfahan, Iran2
Animal Health and Zoonosis PhD Course, Department of Veterinary Medicine, University of Bari, Bari, Italy3
Doctoral School of Molecular Medicine, University of Debrecen, Debrecen, Hungary4
Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary5
School of Public Health, University of Nevada, Las Vegas, Nevada, USA6
Department of Biotechnology, Inland Norway University of Applied Science, Hamar, Hedmark, Norway7
Department of Internal Medicine, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
Implication for health policy/practice/research/medical education:
COVID-19 is a viral disease that first emerged in December 2019, Wuhan, China. In a short time, the disease spread and the world faced with a new pandemic. Since then, great effort implanted to produce effective vaccines and medications for the disease. Nirmatrelvir (PF07321332) is a new drug developed by Pfizer, Inc for COVID-19 treatment. In this essay, we stated recent findings about Nirmatrelvir.
Please cite this paper as: Hajian MR, Jahantigh HR, Alimohammadi S, Mojtahedi Z, Kianpour N, Foroutan M. Nirmatrelvir, a novel medication for COVID-19 treatment. J Nephropharmacol. 2023;12(1):e10486. DOI: 10.34172/npj.2021.10486.